Mayo Clinic Pharmacy Grand Rounds https://pharmacygrandrounds.podbean.com A weekly podcast for pharmacists, physicians, physician assistants, and nurse practitioners who are interested in learning more about clinical pharmacology topics. To claim pharmacology CE credit or to get a copy of presentation slides, visit https://ce.mayo.edu/pharmacypodcast. Produced by @MayoMedEd. Hosted by @garrett_schramm. Wed, 18 Dec 2024 06:00:00 -0600 https://podbean.com/?v=5.5 en © 2020 Mayo Foundation for Medical Education and Research Education 1440 episodic A weekly podcast for pharmacists, physicians, physician assistants, and nurse practitioners who are interested in learning more about clinical pharmacology topics. To claim pharmacology CE credit or to get a copy of presentation slides, visit https://ce.mayo.edu/pharmacypodcast. Produced by @MayoMedEd. Hosted by @garrett_schramm Mayo Clinic Mayo Clinic No false https://pbcdn1.podbean.com/imglogo/image-logo/8934598/Pharmacy_Grand_Rounds_Pill_3000x300094c7s.png Mayo Clinic Pharmacy Grand Rounds https://pharmacygrandrounds.podbean.com 144 144 Statin’ the Facts for HIV Heart Health: Insights from the REPRIEVE Study Statin’ the Facts for HIV Heart Health: Insights from the REPRIEVE Study https://mayoclinicpharmacygrandrounds.podbean.com/e/statin-the-facts-for-hiv-heart-health-insights-from-the-reprieve-study/ https://mayoclinicpharmacygrandrounds.podbean.com/e/statin-the-facts-for-hiv-heart-health-insights-from-the-reprieve-study/#comments Wed, 18 Dec 2024 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/47fec6a2-230a-3f13-9e7d-cef39c7756e8 Damon Alvarez, PharmD, MBA provides insights on statin use in people living with HIV.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Damon Alvarez, PharmD, MBA provides insights on statin use in people living with HIV.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Mayo Clinic false No 2151 194 full The B1 and Only: Evaluation of Thiamine in Septic Shock The B1 and Only: Evaluation of Thiamine in Septic Shock https://mayoclinicpharmacygrandrounds.podbean.com/e/the-b1-and-only-evaluation-of-thiamine-in-septic-shock/ https://mayoclinicpharmacygrandrounds.podbean.com/e/the-b1-and-only-evaluation-of-thiamine-in-septic-shock/#comments Wed, 11 Dec 2024 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/06adbea1-b6b0-381e-9db7-bf015f9dfe6c Kennedy Concannon, PharmD discusses the use of thiamine in septic shock.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

 

]]> Kennedy Concannon, PharmD discusses the use of thiamine in septic shock.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

 

]]> Mayo Clinic false No 1939 193 full Mu’tually Beneficial? Buprenorphine Induction Strategies for OUD Mu’tually Beneficial? Buprenorphine Induction Strategies for OUD https://mayoclinicpharmacygrandrounds.podbean.com/e/mu-tually-beneficial-buprenorphine-induction-strategies-for-oud/ https://mayoclinicpharmacygrandrounds.podbean.com/e/mu-tually-beneficial-buprenorphine-induction-strategies-for-oud/#comments Wed, 04 Dec 2024 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/0c34437b-b175-3cac-9ef2-89f6a8e82404 Katie Bye, PharmD shares insights on buprenorphine induction strategies for opioid use disorders.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Katie Bye, PharmD shares insights on buprenorphine induction strategies for opioid use disorders.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Mayo Clinic false No 2857 192 full Antidotes or Ambiguity? Understanding the use of uridine triacetate and glucarpidase in chemotherapy toxicity. Antidotes or Ambiguity? Understanding the use of uridine triacetate and glucarpidase in chemotherapy toxicity. https://mayoclinicpharmacygrandrounds.podbean.com/e/antidotes-or-ambiguity-understanding-the-use-of-uridine-triacetate-and-glucarpidase-in-chemotherapy-toxicity-1727219643/ https://mayoclinicpharmacygrandrounds.podbean.com/e/antidotes-or-ambiguity-understanding-the-use-of-uridine-triacetate-and-glucarpidase-in-chemotherapy-toxicity-1727219643/#comments Wed, 27 Nov 2024 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/1a33282e-d7e7-3600-8ce9-3146de8ef1f0 Brandy Hernandez, PharmD shares nuances on the use of uridine triacetate and glucarpidase in chemotherapy toxicity management

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Brandy Hernandez, PharmD shares nuances on the use of uridine triacetate and glucarpidase in chemotherapy toxicity management

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Mayo Clinic false No 2114 195 full Too Much Pressure? Non-Selective Beta-Blocker Use in Portal Hypertension Too Much Pressure? Non-Selective Beta-Blocker Use in Portal Hypertension https://mayoclinicpharmacygrandrounds.podbean.com/e/too-much-pressure-non-selective-beta-blocker-use-in-portal-hypertension/ https://mayoclinicpharmacygrandrounds.podbean.com/e/too-much-pressure-non-selective-beta-blocker-use-in-portal-hypertension/#comments Wed, 20 Nov 2024 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/fc6b4873-a878-351d-8435-9499018aa987 Taylor Gullickson, PharmD educates on the use of beta-blockers in portal hypertension

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Taylor Gullickson, PharmD educates on the use of beta-blockers in portal hypertension

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Mayo Clinic false No 1989 190 full Get the Knack for NAC: Management of Acetaminophen Overdoses Get the Knack for NAC: Management of Acetaminophen Overdoses https://mayoclinicpharmacygrandrounds.podbean.com/e/get-the-knack-for-nac-management-of-acetaminophen-overdoses/ https://mayoclinicpharmacygrandrounds.podbean.com/e/get-the-knack-for-nac-management-of-acetaminophen-overdoses/#comments Wed, 13 Nov 2024 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/0a45dde4-1fc3-3467-b8ad-f27d958de64b Megan Edwards, PharmD discusses optimal management of acetaminophen overdose.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Megan Edwards, PharmD discusses optimal management of acetaminophen overdose.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Mayo Clinic false No 2281 189 full Throm-B-Gone: Optimizing the Timing of Anticoagulation After Stroke Secondary to Atrial Fibrillation Throm-B-Gone: Optimizing the Timing of Anticoagulation After Stroke Secondary to Atrial Fibrillation https://mayoclinicpharmacygrandrounds.podbean.com/e/throm-b-gone-optimizing-the-timing-of-anticoagulation-after-stroke-secondary-to-atrial-fibrillation/ https://mayoclinicpharmacygrandrounds.podbean.com/e/throm-b-gone-optimizing-the-timing-of-anticoagulation-after-stroke-secondary-to-atrial-fibrillation/#comments Wed, 06 Nov 2024 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/9c7f081f-f034-3c6f-978b-7766d21736ca Micaela Warfield, PharmD shares updates on the timing of anticoagulation following stroke secondary to atrial fibrillation.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Micaela Warfield, PharmD shares updates on the timing of anticoagulation following stroke secondary to atrial fibrillation.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Mayo Clinic false No 2232 188 full Time to be Suc-SYNCytial: Managing Respiratory Syncytial Virus in HSCT Patients Time to be Suc-SYNCytial: Managing Respiratory Syncytial Virus in HSCT Patients https://mayoclinicpharmacygrandrounds.podbean.com/e/time-to-be-suc-syncytial-managing-respiratory-syncytial-virus-in-hsct-patients/ https://mayoclinicpharmacygrandrounds.podbean.com/e/time-to-be-suc-syncytial-managing-respiratory-syncytial-virus-in-hsct-patients/#comments Wed, 30 Oct 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/4bd55631-bc38-30c9-96e2-f87a14be1851 Jake Noble, PharmD, MPH reviews management of respiratory syncytial virus in patients undergoing allogeneic hematopoietic stem cell transplant.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Jake Noble, PharmD, MPH reviews management of respiratory syncytial virus in patients undergoing allogeneic hematopoietic stem cell transplant.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Mayo Clinic false No 2455 187 full To Hold or Not to Hold? The Use of Metformin with Contrast Media Inpatient and Incretin Mimetics Perioperatively To Hold or Not to Hold? The Use of Metformin with Contrast Media Inpatient and Incretin Mimetics Perioperatively https://mayoclinicpharmacygrandrounds.podbean.com/e/to-hold-or-not-to-hold-the-use-of-metformin-with-contrast-media-inpatient-and-incretin-mimetics-perioperatively/ https://mayoclinicpharmacygrandrounds.podbean.com/e/to-hold-or-not-to-hold-the-use-of-metformin-with-contrast-media-inpatient-and-incretin-mimetics-perioperatively/#comments Wed, 23 Oct 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/6fbd3f6c-d2ba-3594-bb1b-ecc6d95efe88 Caitlin Schanz, PharmD & Krysta Larson, PharmD review metformin use inpatient and incretin mimetic use perioperatively.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Caitlin Schanz, PharmD & Krysta Larson, PharmD review metformin use inpatient and incretin mimetic use perioperatively.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Mayo Clinic false No 2366 186 full Aminoglycosides and MT-RNR1: a Drug-Gene Interaction You May Not Have Heard About Aminoglycosides and MT-RNR1: a Drug-Gene Interaction You May Not Have Heard About https://mayoclinicpharmacygrandrounds.podbean.com/e/aminoglycosides-and-mt-rnr1-a-drug-gene-interaction-you-may-not-have-heard-about/ https://mayoclinicpharmacygrandrounds.podbean.com/e/aminoglycosides-and-mt-rnr1-a-drug-gene-interaction-you-may-not-have-heard-about/#comments Wed, 16 Oct 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/f8df46bd-3807-3906-8727-549b3080584c Alex McCarthy, PharmD, MS discusses aminoglycoside induced hearing loss and genetic testing.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Alex McCarthy, PharmD, MS discusses aminoglycoside induced hearing loss and genetic testing.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Mayo Clinic false No 2169 185 full Extending Compassion Through Expanded Access to Investigational Medicine Extending Compassion Through Expanded Access to Investigational Medicine https://mayoclinicpharmacygrandrounds.podbean.com/e/extending-compassion-through-expanded-access-to-investigational-medicine/ https://mayoclinicpharmacygrandrounds.podbean.com/e/extending-compassion-through-expanded-access-to-investigational-medicine/#comments Wed, 09 Oct 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/aaa79eee-2a5e-33cd-b270-194b1c56aa6d Trinkal Patel, PharmD shares insights on compassionate use and investigational medicine.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Trinkal Patel, PharmD shares insights on compassionate use and investigational medicine.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Mayo Clinic false No 2146 184 full A Whole LADA Mystery: Uncovering Latent Autoimmune Diabetes in Adults A Whole LADA Mystery: Uncovering Latent Autoimmune Diabetes in Adults https://mayoclinicpharmacygrandrounds.podbean.com/e/a-whole-lada-mystery-uncovering-latent-autoimmune-diabetes-in-adults/ https://mayoclinicpharmacygrandrounds.podbean.com/e/a-whole-lada-mystery-uncovering-latent-autoimmune-diabetes-in-adults/#comments Wed, 02 Oct 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/f9cf615f-9170-3f31-80d5-855b11dc2b37 Krista Olson, PharmD reviews pharmacotherapeutic approaches to latent autoimmune diabetes in adults.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Krista Olson, PharmD reviews pharmacotherapeutic approaches to latent autoimmune diabetes in adults.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Mayo Clinic false No 1947 183 full Interoperability: When devices have a conversation Interoperability: When devices have a conversation https://mayoclinicpharmacygrandrounds.podbean.com/e/interoperability-when-devices-have-a-conversation/ https://mayoclinicpharmacygrandrounds.podbean.com/e/interoperability-when-devices-have-a-conversation/#comments Wed, 25 Sep 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/bc0031f0-7074-35f5-b34c-11c289b6b7ef Sherwyn Tenia, PharmD, MBA, BCPS, PMP explores interoperability with a focus on smart infusion pumps.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Sherwyn Tenia, PharmD, MBA, BCPS, PMP explores interoperability with a focus on smart infusion pumps.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. 

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

]]> Mayo Clinic false No 2549 182 full Feeling a Bit Psor? Pharmacological Treatment Options in Psoriasis Feeling a Bit Psor? Pharmacological Treatment Options in Psoriasis https://mayoclinicpharmacygrandrounds.podbean.com/e/feeling-a-bit-psor-pharmacological-treatment-options-in-psoriasis/ https://mayoclinicpharmacygrandrounds.podbean.com/e/feeling-a-bit-psor-pharmacological-treatment-options-in-psoriasis/#comments Wed, 18 Sep 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/e579f18a-19b3-3c4b-b0a4-41a8775d0666 Nate Johnson, PharmD, BCPS discusses updates in the pharmacologic treatment for psoriasis.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

]]> Nate Johnson, PharmD, BCPS discusses updates in the pharmacologic treatment for psoriasis.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

]]> Mayo Clinic false No 2850 181 full Beyond Dispensing: Pioneering the Future of Pharmacy Services Beyond Dispensing: Pioneering the Future of Pharmacy Services https://mayoclinicpharmacygrandrounds.podbean.com/e/beyond-dispensing-pioneering-the-future-of-pharmacy-services/ https://mayoclinicpharmacygrandrounds.podbean.com/e/beyond-dispensing-pioneering-the-future-of-pharmacy-services/#comments Wed, 10 Jul 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/d16588b9-69b2-32a3-b578-d665966173b6 Mark Layden discusses pharmacy quality outcomes, metrics, and the future direction of justifying clinical pharmacy services.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

]]> Mark Layden discusses pharmacy quality outcomes, metrics, and the future direction of justifying clinical pharmacy services.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

]]> Mayo Clinic false No 2885 180 full Breaking it Down: Pseudomonas aeruginosa Resistance Breaking it Down: Pseudomonas aeruginosa Resistance https://mayoclinicpharmacygrandrounds.podbean.com/e/breaking-it-down-pseudomonas-aeruginosa-resistance/ https://mayoclinicpharmacygrandrounds.podbean.com/e/breaking-it-down-pseudomonas-aeruginosa-resistance/#comments Wed, 03 Jul 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/33ff0216-1a08-3f9c-9a0d-8c6ae9bdd26d Jenna Jackson we will review mechanisms of resistance, management of multidrug resistant infections, and antimicrobial development.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

 

]]> Jenna Jackson we will review mechanisms of resistance, management of multidrug resistant infections, and antimicrobial development.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

 

]]> Mayo Clinic false No 2065 179 full Scratching the Itch: The Role of the Pharmacist in De-Labeling Antimicrobial Agents Scratching the Itch: The Role of the Pharmacist in De-Labeling Antimicrobial Agents https://mayoclinicpharmacygrandrounds.podbean.com/e/scratching-the-itch-the-role-of-the-pharmacist-in-de-labeling-antimicrobial-agents/ https://mayoclinicpharmacygrandrounds.podbean.com/e/scratching-the-itch-the-role-of-the-pharmacist-in-de-labeling-antimicrobial-agents/#comments Wed, 26 Jun 2024 08:38:24 -0500 mayoclinicpharmacygrandrounds.podbean.com/e8058cc7-fbf2-339b-b1ef-a647f110a871 Matt Neumann, PharmD outlines recommendations to manage patients with penicillin and other antimicrobial allergy labels.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

]]> Matt Neumann, PharmD outlines recommendations to manage patients with penicillin and other antimicrobial allergy labels.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

]]> Mayo Clinic false No 1905 178 full Is Rate Control the Rate-limiting Step in Management of Atrial Fibrillation? Rate versus Rhythm Control with a Focus on Antiarrhythmic Drugs Is Rate Control the Rate-limiting Step in Management of Atrial Fibrillation? Rate versus Rhythm Control with a Focus on Antiarrhythmic Drugs https://mayoclinicpharmacygrandrounds.podbean.com/e/is-rate-control-the-rate-limiting-step-in-management-of-atrial-fibrillation-rate-versus-rhythm-control-with-a-focus-on-antiarrhythmic-drugs/ https://mayoclinicpharmacygrandrounds.podbean.com/e/is-rate-control-the-rate-limiting-step-in-management-of-atrial-fibrillation-rate-versus-rhythm-control-with-a-focus-on-antiarrhythmic-drugs/#comments Wed, 19 Jun 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/aeebfa4b-1990-3f55-b43a-46fc3349b680 Alyssa Pitterle, PharmD compares rate and rhythm control in the management of atrial fibrillation with a focus on pharmacotherapy. 

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

 

]]> Alyssa Pitterle, PharmD compares rate and rhythm control in the management of atrial fibrillation with a focus on pharmacotherapy. 

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

 

]]> Mayo Clinic false No 1874 177 full When is Seizure Prophylaxis Indicated in Traumatic Brain Injury: Seizing the Opportunity When is Seizure Prophylaxis Indicated in Traumatic Brain Injury: Seizing the Opportunity https://mayoclinicpharmacygrandrounds.podbean.com/e/when-is-seizure-prophylaxis-indicated-in-traumatic-brain-injury-seizing-the-opportunity/ https://mayoclinicpharmacygrandrounds.podbean.com/e/when-is-seizure-prophylaxis-indicated-in-traumatic-brain-injury-seizing-the-opportunity/#comments Wed, 12 Jun 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/93e05703-6a67-3806-b6ba-ffb712d9fd8c Lauren Metropulos, PharmD will review seizure prophylaxis in traumatic brain injury.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

]]> Lauren Metropulos, PharmD will review seizure prophylaxis in traumatic brain injury.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

]]> Mayo Clinic false No 1426 176 full Get Psyched: Legislative Approval of Medical Psychedelics and their Implications Get Psyched: Legislative Approval of Medical Psychedelics and their Implications https://mayoclinicpharmacygrandrounds.podbean.com/e/get-psyched-legislative-approval-of-medical-psychedelics-and-their-implications/ https://mayoclinicpharmacygrandrounds.podbean.com/e/get-psyched-legislative-approval-of-medical-psychedelics-and-their-implications/#comments Wed, 05 Jun 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/ab947cc1-7d7f-3761-8840-dbb20326d804 Natalie Hagy, PharmD, discusses medical use of psychedelics, including legislative and practical considerations for states and hospitals

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

]]> Natalie Hagy, PharmD, discusses medical use of psychedelics, including legislative and practical considerations for states and hospitals

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

]]> Mayo Clinic false No 2384 175 full Tirzepatide: Weighing the Options Tirzepatide: Weighing the Options https://mayoclinicpharmacygrandrounds.podbean.com/e/tirzepatide-weighing-the-options/ https://mayoclinicpharmacygrandrounds.podbean.com/e/tirzepatide-weighing-the-options/#comments Wed, 29 May 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/3a8d39d1-f153-3084-a75b-975e14b79149 Mickenzie Meyers, PharmD shares insights on pharmacotherapeutic approaches to weight loss.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

]]> Mickenzie Meyers, PharmD shares insights on pharmacotherapeutic approaches to weight loss.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

]]> Mayo Clinic false No 1786 174 full Going Against the Graine: Triptans and Cardiovascular Disease Going Against the Graine: Triptans and Cardiovascular Disease https://mayoclinicpharmacygrandrounds.podbean.com/e/going-against-the-graine-triptans-and-cardiovascular-disease/ https://mayoclinicpharmacygrandrounds.podbean.com/e/going-against-the-graine-triptans-and-cardiovascular-disease/#comments Wed, 22 May 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/19402ebd-9425-3768-8d6a-68ac417e5074 Jordyn Erkel, PharmD reviews the connection between migraines and cardiovascular disease.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X at @MayoMedE

]]> Jordyn Erkel, PharmD reviews the connection between migraines and cardiovascular disease.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X at @MayoMedE

]]> Mayo Clinic false No 2259 173 full A Brighter Future: Exploring the Role of Brentuximab vedotin in Pediatric Hodgkin’s Lymphoma A Brighter Future: Exploring the Role of Brentuximab vedotin in Pediatric Hodgkin’s Lymphoma https://mayoclinicpharmacygrandrounds.podbean.com/e/a-brighter-future-exploring-the-role-of-brentuximab-vedotin-in-pediatric-hodgkin-s-lymphoma/ https://mayoclinicpharmacygrandrounds.podbean.com/e/a-brighter-future-exploring-the-role-of-brentuximab-vedotin-in-pediatric-hodgkin-s-lymphoma/#comments Wed, 15 May 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/dd996bf1-945c-3856-85b7-e0823770cd94 Taylor Gullickson, PharmD explores the role of brentuximab vedotin in pediatric Hodgkin’s lymphoma.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X at @MayoMedE

]]> Taylor Gullickson, PharmD explores the role of brentuximab vedotin in pediatric Hodgkin’s lymphoma.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on X at @MayoMedE

]]> Mayo Clinic false No 1550 172 full Transplanting New Ideas: Updates in Cytomegalovirus Prophylaxis Solid Organ Transplantation Transplanting New Ideas: Updates in Cytomegalovirus Prophylaxis Solid Organ Transplantation https://mayoclinicpharmacygrandrounds.podbean.com/e/transplanting-new-ideas-updates-in-cytomegalovirus-prophylaxis-solid-organ-transplantation/ https://mayoclinicpharmacygrandrounds.podbean.com/e/transplanting-new-ideas-updates-in-cytomegalovirus-prophylaxis-solid-organ-transplantation/#comments Wed, 08 May 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/76c16c09-29a7-3a6c-8f1c-39118f25a098 Kennedy Concannon, PharmD discusses cytomegalovirus prophylaxis in solid organ transplantation.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Kennedy Concannon, PharmD discusses cytomegalovirus prophylaxis in solid organ transplantation.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2222 171 full Infusion Confusion: Defining the Role of Prolonged Infusion Beta-Lactams Infusion Confusion: Defining the Role of Prolonged Infusion Beta-Lactams https://mayoclinicpharmacygrandrounds.podbean.com/e/infusion-confusion-defining-the-role-of-prolonged-infusion-beta-lactams/ https://mayoclinicpharmacygrandrounds.podbean.com/e/infusion-confusion-defining-the-role-of-prolonged-infusion-beta-lactams/#comments Wed, 13 Mar 2024 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/592d1d36-2344-3fcf-8cda-c8a03c970245 Micaela Warfield, PharmD evaluates the role of prolonged infusion of beta-lactam antibiotics.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Micaela Warfield, PharmD evaluates the role of prolonged infusion of beta-lactam antibiotics.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2081 170 full Breathing New Life into COPD Exacerbation Management Breathing New Life into COPD Exacerbation Management https://mayoclinicpharmacygrandrounds.podbean.com/e/breathing-new-life-into-copd-exacerbation-management/ https://mayoclinicpharmacygrandrounds.podbean.com/e/breathing-new-life-into-copd-exacerbation-management/#comments Wed, 06 Mar 2024 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/e49f0d7f-b9f5-3d18-abe6-18cce74bb866 Katie Bye, PharmD provides insights on the management of COPD exacerbations.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Katie Bye, PharmD provides insights on the management of COPD exacerbations.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2548 169 full Pumping Iron: IV Iron Replacement in HFrEF Pumping Iron: IV Iron Replacement in HFrEF https://mayoclinicpharmacygrandrounds.podbean.com/e/pumping-iron-iv-iron-replacement-in-hfref/ https://mayoclinicpharmacygrandrounds.podbean.com/e/pumping-iron-iv-iron-replacement-in-hfref/#comments Wed, 28 Feb 2024 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/71fc9857-0123-39a5-b185-a816e264bfb8 Will Carns, PharmD reviews the role of intravenous iron in the treatment of heart failure with reduced ejection fraction.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.  

]]> Will Carns, PharmD reviews the role of intravenous iron in the treatment of heart failure with reduced ejection fraction.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.  

]]> Mayo Clinic false No 1862 168 full Buprenorphine for Opioid Use Disorders: Should you Stop Periop? Buprenorphine for Opioid Use Disorders: Should you Stop Periop? https://mayoclinicpharmacygrandrounds.podbean.com/e/buprenorphine-for-opioid-use-disorders-should-you-stop-periop/ https://mayoclinicpharmacygrandrounds.podbean.com/e/buprenorphine-for-opioid-use-disorders-should-you-stop-periop/#comments Wed, 21 Feb 2024 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/f7a45bf2-5745-3e95-923c-20c4d9e2be36 Julia Branger, PharmD discusses use of buprenorphine in the perioperative period.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Julia Branger, PharmD discusses use of buprenorphine in the perioperative period.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2161 167 full Infectious Risk with Advanced Therapies in Inflammatory Bowel Disease Infectious Risk with Advanced Therapies in Inflammatory Bowel Disease https://mayoclinicpharmacygrandrounds.podbean.com/e/infectious-risk-with-advanced-therapies-in-inflammatory-bowel-disease/ https://mayoclinicpharmacygrandrounds.podbean.com/e/infectious-risk-with-advanced-therapies-in-inflammatory-bowel-disease/#comments Wed, 14 Feb 2024 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/a0d99fb4-93c5-3016-b672-ee40d16c343b Megan Edwards, PharmD shares insights on navigating infection risk with advanced therapies for inflammatory bowel disease.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Megan Edwards, PharmD shares insights on navigating infection risk with advanced therapies for inflammatory bowel disease.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2105 166 full Starving for Answers: Parenteral Nutrition in the Critically Ill Starving for Answers: Parenteral Nutrition in the Critically Ill https://mayoclinicpharmacygrandrounds.podbean.com/e/starving-for-answers-parenteral-nutrition-in-the-critically-ill/ https://mayoclinicpharmacygrandrounds.podbean.com/e/starving-for-answers-parenteral-nutrition-in-the-critically-ill/#comments Wed, 07 Feb 2024 15:49:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/5d56cd8c-ae11-312e-a109-da7e6d550488 Brandy Hernandez, PharmD reviews approaches to nutritional need assessment in critical care.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Brandy Hernandez, PharmD reviews approaches to nutritional need assessment in critical care.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 1825 165 full Statin Intolerance and Clear Alternatives Statin Intolerance and Clear Alternatives https://mayoclinicpharmacygrandrounds.podbean.com/e/statin-intolerance-and-clear-alternatives/ https://mayoclinicpharmacygrandrounds.podbean.com/e/statin-intolerance-and-clear-alternatives/#comments Wed, 31 Jan 2024 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/73051e21-f6f4-366a-a75a-a1faf7486699 Andrea Aguayo, PharmD provides insights on statin intolerance and alternative approaches.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Andrea Aguayo, PharmD provides insights on statin intolerance and alternative approaches.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2156 164 full Nirsevimab: Prevent RSV or Let it Be? Nirsevimab: Prevent RSV or Let it Be? https://mayoclinicpharmacygrandrounds.podbean.com/e/nirsevimab-prevent-rsv-or-let-it-be/ https://mayoclinicpharmacygrandrounds.podbean.com/e/nirsevimab-prevent-rsv-or-let-it-be/#comments Wed, 24 Jan 2024 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/a8b5e1bb-7276-3bd7-ae77-77dfd9b352c6 Kimberly James, PharmD shares developments on respiratory syncytial virus (RSV) prevention in infants.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Kimberly James, PharmD shares developments on respiratory syncytial virus (RSV) prevention in infants.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2077 163 full Starting off STRONG: Optimizing Heart Failure Treatment at Transitions of Care Starting off STRONG: Optimizing Heart Failure Treatment at Transitions of Care https://mayoclinicpharmacygrandrounds.podbean.com/e/starting-off-strong-optimizing-heart-failure-treatment-at-transitions-of-care/ https://mayoclinicpharmacygrandrounds.podbean.com/e/starting-off-strong-optimizing-heart-failure-treatment-at-transitions-of-care/#comments Wed, 17 Jan 2024 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/c74ee6ad-62a8-3981-ab7c-bbc5d112b915 Krysta Larson, PharmD provides updates on heart failure treatment strategies in transitions of care.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Krysta Larson, PharmD provides updates on heart failure treatment strategies in transitions of care.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2453 162 full When Drugs BITE Back: Managing Toxicities of Bispecific T-Cell Engagers When Drugs BITE Back: Managing Toxicities of Bispecific T-Cell Engagers https://mayoclinicpharmacygrandrounds.podbean.com/e/when-drugs-bite-back-managing-toxicities-of-bispecific-t-cell-engagers/ https://mayoclinicpharmacygrandrounds.podbean.com/e/when-drugs-bite-back-managing-toxicities-of-bispecific-t-cell-engagers/#comments Wed, 10 Jan 2024 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/1d159718-2131-3150-b820-67895fac9a07 Jenna Puttkamer, PharmD shares insights into toxicity management of bispecific t-cell engagers.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Jenna Puttkamer, PharmD shares insights into toxicity management of bispecific t-cell engagers.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2062 161 full Colchi(seen) to Reduce Cardiovascular Risk in Established ASCVD Colchi(seen) to Reduce Cardiovascular Risk in Established ASCVD https://mayoclinicpharmacygrandrounds.podbean.com/e/colchiseen-to-reduce-cardiovascular-risk-in-established-ascvd/ https://mayoclinicpharmacygrandrounds.podbean.com/e/colchiseen-to-reduce-cardiovascular-risk-in-established-ascvd/#comments Wed, 13 Dec 2023 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/f7aacd3f-c4cb-397e-a4e7-6c6cec494d9b Maggie Ruschmeyer, PharmD reviews the evidence in colchicine for secondary prevention of ASCVD.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Maggie Ruschmeyer, PharmD reviews the evidence in colchicine for secondary prevention of ASCVD.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2263 160 full It’s Not All Negative: Antibody Drug Conjugates in HER-2 Low Breast Cancer It’s Not All Negative: Antibody Drug Conjugates in HER-2 Low Breast Cancer https://mayoclinicpharmacygrandrounds.podbean.com/e/it-s-not-all-negative-antibody-drug-conjugates-in-her-2-low-breast-cancer/ https://mayoclinicpharmacygrandrounds.podbean.com/e/it-s-not-all-negative-antibody-drug-conjugates-in-her-2-low-breast-cancer/#comments Wed, 06 Dec 2023 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/41eb25aa-8552-39ef-819c-525c47ee9913 Brianna Chambers, PharmD describes the landscape for HER-2 low classification in the treatment of breast cancer.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Brianna Chambers, PharmD describes the landscape for HER-2 low classification in the treatment of breast cancer.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2111 159 full The Intensive Approach: Updates for Blood Pressure Control in Intracerebral Hemorrhage The Intensive Approach: Updates for Blood Pressure Control in Intracerebral Hemorrhage https://mayoclinicpharmacygrandrounds.podbean.com/e/the-intensive-approach-updates-for-blood-pressure-control-in-intracerebral-hemorrhage/ https://mayoclinicpharmacygrandrounds.podbean.com/e/the-intensive-approach-updates-for-blood-pressure-control-in-intracerebral-hemorrhage/#comments Wed, 29 Nov 2023 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/5e778397-54e5-3269-879d-24bdc0b5d86c Allie Curran, PharmD reviews blood pressure management strategies in intracerebral hemorrhage.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Allie Curran, PharmD reviews blood pressure management strategies in intracerebral hemorrhage.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2083 158 full My, Oh, Myocarditis: More to Monitor for Clozapine? My, Oh, Myocarditis: More to Monitor for Clozapine? https://mayoclinicpharmacygrandrounds.podbean.com/e/my-oh-myocarditis-more-to-monitor-for-clozapine/ https://mayoclinicpharmacygrandrounds.podbean.com/e/my-oh-myocarditis-more-to-monitor-for-clozapine/#comments Wed, 15 Nov 2023 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/6ac250cf-d4ce-3867-a26f-ad80cb62ec4c Caitlin Schanz, PharmD discusses considerations for clozapine-induced myocarditis.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Caitlin Schanz, PharmD discusses considerations for clozapine-induced myocarditis.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2472 157 full Going Viral! Reactivation of Viral Infections Following Cancer Treatment Going Viral! Reactivation of Viral Infections Following Cancer Treatment https://mayoclinicpharmacygrandrounds.podbean.com/e/going-viral-reactivation-of-viral-infections-following-cancer-treatment/ https://mayoclinicpharmacygrandrounds.podbean.com/e/going-viral-reactivation-of-viral-infections-following-cancer-treatment/#comments Wed, 08 Nov 2023 15:34:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/cea34896-dec0-3b53-8dbf-8d5804a9de88 Abdullah Al-Ajmi, PharmD, BCPS reviews approaches to viral reactivation following cancer treatment.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Abdullah Al-Ajmi, PharmD, BCPS reviews approaches to viral reactivation following cancer treatment.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2253 156 full Don’t Lose Your Nerve: Supporting the Denervated Heart after Cardiac Transplantation Don’t Lose Your Nerve: Supporting the Denervated Heart after Cardiac Transplantation https://mayoclinicpharmacygrandrounds.podbean.com/e/don-t-lose-your-nerve-supporting-the-denervated-heart-after-cardiac-transplantation/ https://mayoclinicpharmacygrandrounds.podbean.com/e/don-t-lose-your-nerve-supporting-the-denervated-heart-after-cardiac-transplantation/#comments Wed, 01 Nov 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/28f744e5-7d13-35c3-a9d2-b4b074a0160e Tanner Melton, PharmD reviews pharmacologic management of post cardiac transplant.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Tanner Melton, PharmD reviews pharmacologic management of post cardiac transplant.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2285 155 full Shocking Update: The Use of Fludrocortisone in Septic Shock Shocking Update: The Use of Fludrocortisone in Septic Shock https://mayoclinicpharmacygrandrounds.podbean.com/e/shocking-update-the-use-of-fludrocortisone-in-septic-shock/ https://mayoclinicpharmacygrandrounds.podbean.com/e/shocking-update-the-use-of-fludrocortisone-in-septic-shock/#comments Wed, 25 Oct 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/43ce0393-edf1-3d75-a241-41556f71eca5 Hailey Thompson, PharmD shares SHOCKing updates on the use of corticosteroids in septic shock.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Hailey Thompson, PharmD shares SHOCKing updates on the use of corticosteroids in septic shock.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2573 154 full Bad Blood: Anemia Management Updates in the Setting of Chronic Kidney Disease Bad Blood: Anemia Management Updates in the Setting of Chronic Kidney Disease https://mayoclinicpharmacygrandrounds.podbean.com/e/bad-blood-anemia-management-updates-in-the-setting-of-chronic-kidney-disease/ https://mayoclinicpharmacygrandrounds.podbean.com/e/bad-blood-anemia-management-updates-in-the-setting-of-chronic-kidney-disease/#comments Wed, 18 Oct 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/0a6d1800-a3a8-3a04-9f13-b70399a0b7d8 Mark Layden, PharmD, MBA shares the place in therapy for hypoxia-inducible factor prolyl hydroxylase inhibitors and other general approaches to anemia management in chronic kidney disease.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mark Layden, PharmD, MBA shares the place in therapy for hypoxia-inducible factor prolyl hydroxylase inhibitors and other general approaches to anemia management in chronic kidney disease.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2165 153 full A Rumble in the Fungal Jungle: Review of the New Antifungal Agents A Rumble in the Fungal Jungle: Review of the New Antifungal Agents https://mayoclinicpharmacygrandrounds.podbean.com/e/a-rumble-in-the-fungal-jungle-review-of-the-new-antifungal-agents/ https://mayoclinicpharmacygrandrounds.podbean.com/e/a-rumble-in-the-fungal-jungle-review-of-the-new-antifungal-agents/#comments Wed, 11 Oct 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/1ccebbcd-aeef-3dec-9134-4f073da77f19 Natalie T. Hagy, PharmD shares new antifungal agents in the pipeline, their novel mechanisms of action, and available formulations.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Natalie T. Hagy, PharmD shares new antifungal agents in the pipeline, their novel mechanisms of action, and available formulations.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2012 152 full Lost in the ECMO Chamber: Pharmacokinetics in Critical Illness Lost in the ECMO Chamber: Pharmacokinetics in Critical Illness https://mayoclinicpharmacygrandrounds.podbean.com/e/lost-in-the-ecmo-chamber-pharmacokinetics-in-critical-illness/ https://mayoclinicpharmacygrandrounds.podbean.com/e/lost-in-the-ecmo-chamber-pharmacokinetics-in-critical-illness/#comments Wed, 04 Oct 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/6840f57e-08a1-3cfb-a88f-795afc2fe115 Ming May Zhang, PharmD reviews pharmacokinetic considerations in extracorporeal membrane oxygenation.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Ming May Zhang, PharmD reviews pharmacokinetic considerations in extracorporeal membrane oxygenation.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2240 151 full Must be mAb on the Brain: A New Hope for Alzheimer’s Disease Must be mAb on the Brain: A New Hope for Alzheimer’s Disease https://mayoclinicpharmacygrandrounds.podbean.com/e/must-be-mab-on-the-brain-a-new-hope-for-alzheimer-s-disease/ https://mayoclinicpharmacygrandrounds.podbean.com/e/must-be-mab-on-the-brain-a-new-hope-for-alzheimer-s-disease/#comments Wed, 13 Sep 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/e0610854-310b-3d6a-a268-f47606142da3 Hailey Thompson, PharmD, reviews primary literature and shares updates on the role of monoclonal antibody therapies in the treatment of Alzheimer’s Disease.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Hailey Thompson, PharmD, reviews primary literature and shares updates on the role of monoclonal antibody therapies in the treatment of Alzheimer’s Disease.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2570 150 full GPS for APS: Navigating Anticoagulation in Antiphospholipid Syndrome GPS for APS: Navigating Anticoagulation in Antiphospholipid Syndrome https://mayoclinicpharmacygrandrounds.podbean.com/e/gps-for-aps-navigating-anticoagulation-in-antiphospholipid-syndrome/ https://mayoclinicpharmacygrandrounds.podbean.com/e/gps-for-aps-navigating-anticoagulation-in-antiphospholipid-syndrome/#comments Wed, 06 Sep 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/d0de1ec8-61ba-3ef6-9d57-099eb675a12d Caitlin Schanz, PharmD discusses antiphospholipid syndrome, with a focus on data comparing direct oral anticoagulants versus warfarin as anticoagulation strategies in these patients.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Caitlin Schanz, PharmD discusses antiphospholipid syndrome, with a focus on data comparing direct oral anticoagulants versus warfarin as anticoagulation strategies in these patients.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2447 149 full Waving Goodbye to the X Waiver: Reassessing Medication Treatment for Opioid Use Disorder Waving Goodbye to the X Waiver: Reassessing Medication Treatment for Opioid Use Disorder https://mayoclinicpharmacygrandrounds.podbean.com/e/waving-goodbye-to-the-x-waiver-reassessing-medication-treatment-for-opioid-use-disorder/ https://mayoclinicpharmacygrandrounds.podbean.com/e/waving-goodbye-to-the-x-waiver-reassessing-medication-treatment-for-opioid-use-disorder/#comments Wed, 30 Aug 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/729151b6-6eb2-33d6-be1a-8b7136c0e6f4 Tanner Melton, PharmD reviews literature on buprenorphine and methadone in treating opioid use disorder.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Tanner Melton, PharmD reviews literature on buprenorphine and methadone in treating opioid use disorder.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2825 148 full Give it a Shot! Long-Acting Injectables in HIV Therapy Give it a Shot! Long-Acting Injectables in HIV Therapy https://mayoclinicpharmacygrandrounds.podbean.com/e/give-it-a-shot-long-acting-injectables-in-hiv-therapy/ https://mayoclinicpharmacygrandrounds.podbean.com/e/give-it-a-shot-long-acting-injectables-in-hiv-therapy/#comments Wed, 23 Aug 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/55f5d4d6-c711-3315-9caf-383ac25a78ee Christopher Cahoon, PharmD elucidates the literature pertaining to injectable cabotegravir and rilpivirine as HIV therapy options.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Christopher Cahoon, PharmD elucidates the literature pertaining to injectable cabotegravir and rilpivirine as HIV therapy options.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2527 147 full Taking the LEAD? Dual Pathway Inhibition Therapy for Lower Extremity Arterial Disease Taking the LEAD? Dual Pathway Inhibition Therapy for Lower Extremity Arterial Disease https://mayoclinicpharmacygrandrounds.podbean.com/e/taking-the-lead-dual-pathway-inhibition-therapy-for-lower-extremity-arterial-disease/ https://mayoclinicpharmacygrandrounds.podbean.com/e/taking-the-lead-dual-pathway-inhibition-therapy-for-lower-extremity-arterial-disease/#comments Wed, 16 Aug 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/170f6478-17b4-3af5-9643-73e06a2ae847 Shienna Braga, PharmD examines the literature pertaining to dual pathway inhibition for lower extremity arterial disease.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Shienna Braga, PharmD examines the literature pertaining to dual pathway inhibition for lower extremity arterial disease.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2623 146 full What’s Been ‘Flozin On: Updates in Outpatient Management of Chronic Kidney Disease What’s Been ‘Flozin On: Updates in Outpatient Management of Chronic Kidney Disease https://mayoclinicpharmacygrandrounds.podbean.com/e/what-s-been-flozin-on-updates-in-outpatient-management-of-chronic-kidney-disease/ https://mayoclinicpharmacygrandrounds.podbean.com/e/what-s-been-flozin-on-updates-in-outpatient-management-of-chronic-kidney-disease/#comments Wed, 09 Aug 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/6c68eab1-8b9b-3c3d-9fe2-0ad0f038db92 Lauren Stonerock, PharmD describes updates in outpatient management of chronic kidney disease.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Lauren Stonerock, PharmD describes updates in outpatient management of chronic kidney disease.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2356 145 full Celebrating diversity: challenges and strategies to promote pharmacogenomics translation across populations Celebrating diversity: challenges and strategies to promote pharmacogenomics translation across populations https://mayoclinicpharmacygrandrounds.podbean.com/e/celebrating-diversity-challenges-and-strategies-to-promote-pharmacogenomics-translation-across-populations/ https://mayoclinicpharmacygrandrounds.podbean.com/e/celebrating-diversity-challenges-and-strategies-to-promote-pharmacogenomics-translation-across-populations/#comments Wed, 02 Aug 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/c913180e-33ad-340b-b657-7fdd8d051cb2 Serena Mitaly, PharmD shares strategies for pharmacogenomic research translation to reduce health disparities.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Serena Mitaly, PharmD shares strategies for pharmacogenomic research translation to reduce health disparities.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 1738 144 full What’s the Best for CRS? What’s the Best for CRS? https://mayoclinicpharmacygrandrounds.podbean.com/e/what-s-the-best-for-crs/ https://mayoclinicpharmacygrandrounds.podbean.com/e/what-s-the-best-for-crs/#comments Wed, 26 Jul 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/fe784e8e-d46d-33a5-a462-c069c349f07a Devon Stonerock, PharmD, Uzo Abajue, PharmD and Divya Khandekar, PharmD describe cytokine release syndrome (CRS), the literature surrounding CRS and options for CRS management.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Devon Stonerock, PharmD, Uzo Abajue, PharmD and Divya Khandekar, PharmD describe cytokine release syndrome (CRS), the literature surrounding CRS and options for CRS management.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2855 143 full Pitter Patter, Let’s Get ATTR: Medications for Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) Pitter Patter, Let’s Get ATTR: Medications for Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) https://mayoclinicpharmacygrandrounds.podbean.com/e/pitter-patter-let-s-get-attr-medications-for-transthyretin-amyloidosis-cardiomyopathy-attr-cm/ https://mayoclinicpharmacygrandrounds.podbean.com/e/pitter-patter-let-s-get-attr-medications-for-transthyretin-amyloidosis-cardiomyopathy-attr-cm/#comments Wed, 19 Jul 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/1be9d421-5d6d-3aba-907e-f6c1d75afc9f Kelli Herrin, PharmD reviews the pathophysiology of transthyretin amyloidosis cardiomyopathy and provides updates on medication options.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Kelli Herrin, PharmD reviews the pathophysiology of transthyretin amyloidosis cardiomyopathy and provides updates on medication options.

 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 1846 142 full Updates on the Clozapine REMS Program: An Important Relic or Fool’s Gold of Safety? Updates on the Clozapine REMS Program: An Important Relic or Fool’s Gold of Safety? https://mayoclinicpharmacygrandrounds.podbean.com/e/updates-on-the-clozapine-rems-program-an-important-relic-or-fool-s-gold-of-safety/ https://mayoclinicpharmacygrandrounds.podbean.com/e/updates-on-the-clozapine-rems-program-an-important-relic-or-fool-s-gold-of-safety/#comments Wed, 12 Jul 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/a64e62ce-1505-3772-a3fe-d3e6616e5d33 Jonathan Leung, PharmD, BCPS, BCPP provides updates on the clozapine REMS program, reviews the therapeutic benefits of clozapine, as well as key adverse events.  

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Jonathan Leung, PharmD, BCPS, BCPP provides updates on the clozapine REMS program, reviews the therapeutic benefits of clozapine, as well as key adverse events.  

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2803 141 full On Another Level: The Role of Therapeutic Drug Monitoring in Inflammatory Bowel Disease On Another Level: The Role of Therapeutic Drug Monitoring in Inflammatory Bowel Disease https://mayoclinicpharmacygrandrounds.podbean.com/e/on-another-level-the-role-of-therapeutic-drug-monitoring-in-inflammatory-bowel-disease/ https://mayoclinicpharmacygrandrounds.podbean.com/e/on-another-level-the-role-of-therapeutic-drug-monitoring-in-inflammatory-bowel-disease/#comments Wed, 05 Jul 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/c5771902-d3b5-311d-9778-2172edb078ef Sarah A. Chase, PharmD reviews the pathophysiology and current treatment strategies for inflammatory bowel disease, defines the clinical application of therapeutic drug monitoring of biologic therapies used in inflammatory bowel disease and discusses biologic therapy optimization based on therapeutic drug monitoring.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Sarah A. Chase, PharmD reviews the pathophysiology and current treatment strategies for inflammatory bowel disease, defines the clinical application of therapeutic drug monitoring of biologic therapies used in inflammatory bowel disease and discusses biologic therapy optimization based on therapeutic drug monitoring.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2424 140 full All-In on Insulin? Use of High-Dose Insulin Euglycemic Therapy in Calcium Channel Blocker Overdose All-In on Insulin? Use of High-Dose Insulin Euglycemic Therapy in Calcium Channel Blocker Overdose https://mayoclinicpharmacygrandrounds.podbean.com/e/all-in-on-insulin-use-of-high-dose-insulin-euglycemic-therapy-in-calcium-channel-blocker-overdose/ https://mayoclinicpharmacygrandrounds.podbean.com/e/all-in-on-insulin-use-of-high-dose-insulin-euglycemic-therapy-in-calcium-channel-blocker-overdose/#comments Wed, 28 Jun 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/792c6de1-82ae-3dc0-9d97-e7cba78092f8 Kyle A. Hess, PharmD, BCPS Twitter: @KyleHessPharmD describes the pathophysiology of calcium channel blocker overdose, explains the rationale for use of insulin-euglycemic therapy in calcium channel blocker overdose and identifies differences between the pathophysiology of dihydropyridine overdose and non-dihydropyridine overdose.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Kyle A. Hess, PharmD, BCPS Twitter: @KyleHessPharmD describes the pathophysiology of calcium channel blocker overdose, explains the rationale for use of insulin-euglycemic therapy in calcium channel blocker overdose and identifies differences between the pathophysiology of dihydropyridine overdose and non-dihydropyridine overdose.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2012 139 full Measuring Value in Drug Therapy Measuring Value in Drug Therapy https://mayoclinicpharmacygrandrounds.podbean.com/e/measuring-value-in-drug-therapy/ https://mayoclinicpharmacygrandrounds.podbean.com/e/measuring-value-in-drug-therapy/#comments Wed, 21 Jun 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/9b1b3a4a-eec0-3f8b-b4f1-6203d2216482 Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA (Twitter: @sasoefje) describes the relationship between value and quality, defines quality and how quality measures will impact healthcare in the coming years, and demonstrates how organizations may use quality measures to improve value.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA (Twitter: @sasoefje) describes the relationship between value and quality, defines quality and how quality measures will impact healthcare in the coming years, and demonstrates how organizations may use quality measures to improve value.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2229 138 full Verification Decision Support: May AI Take Your Order? Verification Decision Support: May AI Take Your Order? https://mayoclinicpharmacygrandrounds.podbean.com/e/verification-decision-support-may-ai-take-your-order/ https://mayoclinicpharmacygrandrounds.podbean.com/e/verification-decision-support-may-ai-take-your-order/#comments Wed, 14 Jun 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/f3efee0a-9bb4-3d5f-800e-db68a2df4c9a Benjamin J. Anderson, PharmD, MPH, FASHP and Diana J. Schreier, PharmD, MBA, BCPS recognize the history and regulations for prospective medication order review, describe the technical landscape for verification decision support and explore real-world verification decision support outcomes.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Benjamin J. Anderson, PharmD, MPH, FASHP and Diana J. Schreier, PharmD, MBA, BCPS recognize the history and regulations for prospective medication order review, describe the technical landscape for verification decision support and explore real-world verification decision support outcomes.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2264 137 full A Hard-Pressed Debate: The Role of Terlipressin in Hepatorenal Syndrome A Hard-Pressed Debate: The Role of Terlipressin in Hepatorenal Syndrome https://mayoclinicpharmacygrandrounds.podbean.com/e/a-hard-pressed-debate-the-role-of-terlipressin-in-hepatorenal-syndrome/ https://mayoclinicpharmacygrandrounds.podbean.com/e/a-hard-pressed-debate-the-role-of-terlipressin-in-hepatorenal-syndrome/#comments Wed, 07 Jun 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/8c26d4e3-8a23-3b0e-be04-e57be559554a Nikitha Yagnala, PharmD and Andy J. Jatis, PharmD, BCPS describe the pathophysiology of hepatorenal syndrome (HRS), describe the pathophysiology of hepatorenal syndrome (HRS) and outline an optimal patient care plan for the management of HRS.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

 

]]> Nikitha Yagnala, PharmD and Andy J. Jatis, PharmD, BCPS describe the pathophysiology of hepatorenal syndrome (HRS), describe the pathophysiology of hepatorenal syndrome (HRS) and outline an optimal patient care plan for the management of HRS.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

 

]]> Mayo Clinic false No 2328 136 full Freezing Ethylene Glycol Toxicity Freezing Ethylene Glycol Toxicity https://mayoclinicpharmacygrandrounds.podbean.com/e/freezing-ethylene-glycol-toxicity/ https://mayoclinicpharmacygrandrounds.podbean.com/e/freezing-ethylene-glycol-toxicity/#comments Wed, 31 May 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/3a95e959-39b9-370b-ba5e-f45e07c26822 Kamryn R. Storm, PharmD (Twitter @KRStorm) outlines the mechanism of toxicity for ethylene glycol, identifies clinical findings of ethylene glycol toxicity and selects treatment regimens for suspected ethylene glycol toxicity.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Kamryn R. Storm, PharmD (Twitter @KRStorm) outlines the mechanism of toxicity for ethylene glycol, identifies clinical findings of ethylene glycol toxicity and selects treatment regimens for suspected ethylene glycol toxicity.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 1880 135 full Emerging Antibiotics – Tetra(cycle)ine Back to Basics Emerging Antibiotics – Tetra(cycle)ine Back to Basics https://mayoclinicpharmacygrandrounds.podbean.com/e/emerging-antibiotics-%e2%80%93-tetracycleine-back-to-basics/ https://mayoclinicpharmacygrandrounds.podbean.com/e/emerging-antibiotics-%e2%80%93-tetracycleine-back-to-basics/#comments Wed, 24 May 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/6c80d79d-fe7d-33dc-b435-9753fef5f1c4 Ashton C. Praska, PharmD (Twitter @ashpraka) describes tetracycline resistance mechanisms utilized by bacteria, identifies how Omadacycline/Eravacycline can overcome common tetracycline resistance mechanisms and identifies clinical scenarios where Omadacycline/Eravacycline could be considered for use.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Ashton C. Praska, PharmD (Twitter @ashpraka) describes tetracycline resistance mechanisms utilized by bacteria, identifies how Omadacycline/Eravacycline can overcome common tetracycline resistance mechanisms and identifies clinical scenarios where Omadacycline/Eravacycline could be considered for use.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 1888 134 full Pharmacotherapy for the Treatment of Obesity Pharmacotherapy for the Treatment of Obesity https://mayoclinicpharmacygrandrounds.podbean.com/e/pharmacotherapy-for-the-treatment-of-obesity/ https://mayoclinicpharmacygrandrounds.podbean.com/e/pharmacotherapy-for-the-treatment-of-obesity/#comments Wed, 17 May 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/b05df355-8a45-3df0-b18e-cc62e273eade Kristina M. Thurber, PharmD, BCPS recognizes pharmacotherapy for the treatment of obesity and explain mechanisms of action for each class, discusses and compares clinical data and weight loss outcomes for common treatment options, and determines an optimal pharmacologic regimen for the treatment of obesity given patient-specific factors.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Kristina M. Thurber, PharmD, BCPS recognizes pharmacotherapy for the treatment of obesity and explain mechanisms of action for each class, discusses and compares clinical data and weight loss outcomes for common treatment options, and determines an optimal pharmacologic regimen for the treatment of obesity given patient-specific factors.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2541 133 full Off the Chain: The Drug Supply Chain and Medication Shortages Off the Chain: The Drug Supply Chain and Medication Shortages https://mayoclinicpharmacygrandrounds.podbean.com/e/off-the-chain-the-drug-supply-chain-and-medication-shortages/ https://mayoclinicpharmacygrandrounds.podbean.com/e/off-the-chain-the-drug-supply-chain-and-medication-shortages/#comments Wed, 10 May 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/3f73c201-3735-3f79-b147-5185574ceeaa Jo Ann Leal, PharmD (Twitter @JoJoPharmD) describes the key components of the drug supply chain and the impact of drug shortages, identifies common organizational strategies used to mitigate drug shortages and evaluates recent national efforts to stabilize the drug supply chain.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Jo Ann Leal, PharmD (Twitter @JoJoPharmD) describes the key components of the drug supply chain and the impact of drug shortages, identifies common organizational strategies used to mitigate drug shortages and evaluates recent national efforts to stabilize the drug supply chain.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2020 132 full Clostridioides difficile Infection: Do We C the Diff-erence in Preventing Recurrence? Clostridioides difficile Infection: Do We C the Diff-erence in Preventing Recurrence? https://mayoclinicpharmacygrandrounds.podbean.com/e/clostridioides-difficile-infection-do-we-c-the-diff-erence-in-preventing-recurrence/ https://mayoclinicpharmacygrandrounds.podbean.com/e/clostridioides-difficile-infection-do-we-c-the-diff-erence-in-preventing-recurrence/#comments Wed, 03 May 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/201e09a6-898b-37ee-82fb-33b9380f32ab Andrew (Andy) F. Wiener, PharmD (Twtitter @andywiener) describes the pathogenesis and risk factors of C. diff infection and recurrence, reviews the preferred treatment modalities for prevention of C. diff recurrence and describes the cost-benefit analysis supporting guideline-directed management of C. diff infections.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Andrew (Andy) F. Wiener, PharmD (Twtitter @andywiener) describes the pathogenesis and risk factors of C. diff infection and recurrence, reviews the preferred treatment modalities for prevention of C. diff recurrence and describes the cost-benefit analysis supporting guideline-directed management of C. diff infections.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2440 131 full Pharmacologic Treatment of Drug Resistant Hypercholesterolemia Pharmacologic Treatment of Drug Resistant Hypercholesterolemia https://mayoclinicpharmacygrandrounds.podbean.com/e/pharmacologic-treatment-of-drug-resistant-hypercholesterolemia/ https://mayoclinicpharmacygrandrounds.podbean.com/e/pharmacologic-treatment-of-drug-resistant-hypercholesterolemia/#comments Wed, 26 Apr 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/659bb07f-760b-32d0-b014-fe8a7ca09a85 Seth M. Kriha, PharmD identifies guideline recommended treatment to reduce LDL-C, evaluates landmark clinical trials for novel therapeutic agents indicated for treatment resistant hypercholesterolemia and develops a pharmacologic care plan for a patient with treatment resistant hypercholesterolemia.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Seth M. Kriha, PharmD identifies guideline recommended treatment to reduce LDL-C, evaluates landmark clinical trials for novel therapeutic agents indicated for treatment resistant hypercholesterolemia and develops a pharmacologic care plan for a patient with treatment resistant hypercholesterolemia.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 1974 130 full It’s Going Tibia Okay: Supportive Bone Health in Oncology It’s Going Tibia Okay: Supportive Bone Health in Oncology https://mayoclinicpharmacygrandrounds.podbean.com/e/it-s-going-tibia-okay-supportive-bone-health-in-oncology/ https://mayoclinicpharmacygrandrounds.podbean.com/e/it-s-going-tibia-okay-supportive-bone-health-in-oncology/#comments Wed, 05 Apr 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/1603b3e9-2740-3596-9865-ffb8c249c029 Christopher R. Cahoon, PharmD defines the importance of optimizing bone health in patients with bone metastases and lytic lesions, describes preferred bone-targeted therapy for patients with malignancy-associated bone disease and discusses the safety limitations associated with bisphosphonates and RANKL inhibitors.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Christopher R. Cahoon, PharmD defines the importance of optimizing bone health in patients with bone metastases and lytic lesions, describes preferred bone-targeted therapy for patients with malignancy-associated bone disease and discusses the safety limitations associated with bisphosphonates and RANKL inhibitors.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2261 129 full Preserving the Future: Fertility Preservation in Cancer Patients Preserving the Future: Fertility Preservation in Cancer Patients https://mayoclinicpharmacygrandrounds.podbean.com/e/preserving-the-future-fertility-preservation-in-cancer-patients/ https://mayoclinicpharmacygrandrounds.podbean.com/e/preserving-the-future-fertility-preservation-in-cancer-patients/#comments Wed, 29 Mar 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/8724f294-cf00-33ed-9cdc-ac229d43949f Shienna A. Braga, PharmD explains the effects of select chemotherapeutic agents on gonadal function and fertility in cancer patients, recognizes the different modalities utilized for fertility preservation in adults and children with cancer and reviews current literature that describes the role of gonadotropin-releasing hormone agonists (GnRHa) in women diagnosed with cancer.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Shienna A. Braga, PharmD explains the effects of select chemotherapeutic agents on gonadal function and fertility in cancer patients, recognizes the different modalities utilized for fertility preservation in adults and children with cancer and reviews current literature that describes the role of gonadotropin-releasing hormone agonists (GnRHa) in women diagnosed with cancer.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2856 128 full SUPPosed SUPPort: Targeted Review of Supplements Recommended in Clinical Practice SUPPosed SUPPort: Targeted Review of Supplements Recommended in Clinical Practice https://mayoclinicpharmacygrandrounds.podbean.com/e/supposed-support-targeted-review-of-supplements-recommended-in-clinical-practice/ https://mayoclinicpharmacygrandrounds.podbean.com/e/supposed-support-targeted-review-of-supplements-recommended-in-clinical-practice/#comments Wed, 22 Mar 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/29c84195-e7e7-3e39-99d1-80e9b52f85a2 Linda Huang, Pharm.D identifies considerations for use of select provider-recommended supplements, describes literature that helps explain use of select supplements in outpatient treatment plans and discusses patient cases that highlight place in therapy for supplement use.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Linda Huang, Pharm.D identifies considerations for use of select provider-recommended supplements, describes literature that helps explain use of select supplements in outpatient treatment plans and discusses patient cases that highlight place in therapy for supplement use.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2537 127 full Bridging the Gap: Controversies in Perioperative Anticoagulation Management Bridging the Gap: Controversies in Perioperative Anticoagulation Management https://mayoclinicpharmacygrandrounds.podbean.com/e/turning-the-page-on-the-monoamine-story-utilizing-the-nmda-pathway-for-major-depressive-disorder/ https://mayoclinicpharmacygrandrounds.podbean.com/e/turning-the-page-on-the-monoamine-story-utilizing-the-nmda-pathway-for-major-depressive-disorder/#comments Wed, 15 Mar 2023 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/82ecb111-53b0-325c-9dea-154655fcd7cd Ming May Zhang, PharmD (Twitter: @amayzhanggg) reviews key bleeding and thromboembolic risks that should be considered in the perioperative setting, describes the current evidence for perioperative warfarin management in atrial fibrillation, venous thromboembolism, and mechanical heart valves and discusses patient- and disease-specific risk factors that may impact decisions regarding perioperative bridging.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Ming May Zhang, PharmD (Twitter: @amayzhanggg) reviews key bleeding and thromboembolic risks that should be considered in the perioperative setting, describes the current evidence for perioperative warfarin management in atrial fibrillation, venous thromboembolism, and mechanical heart valves and discusses patient- and disease-specific risk factors that may impact decisions regarding perioperative bridging.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2591 118 full To Measure or Not to Measure? Prophylactic Enoxaparin Management in Trauma Patients To Measure or Not to Measure? Prophylactic Enoxaparin Management in Trauma Patients https://mayoclinicpharmacygrandrounds.podbean.com/e/to-measure-or-not-to-measure-prophylactic-enoxaparin-management-in-trauma-patients/ https://mayoclinicpharmacygrandrounds.podbean.com/e/to-measure-or-not-to-measure-prophylactic-enoxaparin-management-in-trauma-patients/#comments Wed, 08 Mar 2023 10:38:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/2b1990b1-f189-3264-a818-e7eba282b659 Hailey A. Thompson, PharmD identifies the physiologic factors that increase venous thromboembolism risk in trauma patients, outlines current recommendations and their pitfalls for venous thromboembolism prophylaxis in trauma patients and discusses evidence for anti-Xa monitoring for venous thromboembolism prophylaxis with enoxaparin.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Hailey A. Thompson, PharmD identifies the physiologic factors that increase venous thromboembolism risk in trauma patients, outlines current recommendations and their pitfalls for venous thromboembolism prophylaxis in trauma patients and discusses evidence for anti-Xa monitoring for venous thromboembolism prophylaxis with enoxaparin.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2277 124 full Put on Your Thinking CAP: Steroid Use in Community-Acquired Pneumonia? Put on Your Thinking CAP: Steroid Use in Community-Acquired Pneumonia? https://mayoclinicpharmacygrandrounds.podbean.com/e/put-on-your-thinking-cap-steroid-use-in-community-acquired-pneumonia/ https://mayoclinicpharmacygrandrounds.podbean.com/e/put-on-your-thinking-cap-steroid-use-in-community-acquired-pneumonia/#comments Wed, 01 Mar 2023 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/61715846-d942-387d-971d-8aea3ac5167f Caitlin C. Schanz, PharmD (@Schanz_Caitlin) explains the pharmacological mechanism of steroid use in community-acquired pneumonia treatment, interprets literature assessing use of steroids in management of community-acquired pneumonia and relates efficacy and safety outcomes of steroids in community-acquired pneumonia to a patient case.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Caitlin C. Schanz, PharmD (@Schanz_Caitlin) explains the pharmacological mechanism of steroid use in community-acquired pneumonia treatment, interprets literature assessing use of steroids in management of community-acquired pneumonia and relates efficacy and safety outcomes of steroids in community-acquired pneumonia to a patient case.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 1889 123 full When the CAR-T’s Over: Managing the Long-Term Complications of CAR-T Therapy When the CAR-T’s Over: Managing the Long-Term Complications of CAR-T Therapy https://mayoclinicpharmacygrandrounds.podbean.com/e/when-the-car-t-s-over-managing-the-long-term-complications-of-car-t-therapy/ https://mayoclinicpharmacygrandrounds.podbean.com/e/when-the-car-t-s-over-managing-the-long-term-complications-of-car-t-therapy/#comments Wed, 22 Feb 2023 10:31:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/c04ae563-d16c-3e8a-ba57-33c11dfcb6d8 Alejandro Del Rio Verduzco, PharmD (Twitter: @Alejandro_DRV) defines the different short-term and long-term toxicities of CAR-T therapy, describes evidence for existing management strategies for late-term CAR-T toxicities and identifies evidence and reports of emerging late-term CAR-T toxicities.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Alejandro Del Rio Verduzco, PharmD (Twitter: @Alejandro_DRV) defines the different short-term and long-term toxicities of CAR-T therapy, describes evidence for existing management strategies for late-term CAR-T toxicities and identifies evidence and reports of emerging late-term CAR-T toxicities.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2174 122 full “Seeing R.E.D” Racial and Ethnic Disparities in Cardiovascular Disease State Medication “Seeing R.E.D” Racial and Ethnic Disparities in Cardiovascular Disease State Medication https://mayoclinicpharmacygrandrounds.podbean.com/e/seeing-red-racial-and-ethnic-disparities-in-cardiovascular-disease-state-medication/ https://mayoclinicpharmacygrandrounds.podbean.com/e/seeing-red-racial-and-ethnic-disparities-in-cardiovascular-disease-state-medication/#comments Wed, 15 Feb 2023 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/4cbd3ab2-8102-371d-baf6-f8a277af47fc Aleesha Jantzen, PharmD describes social determinants of health that impact management of cardiovascular disease states, recognizes racial/ethnic disparities in management of atrial fibrillation, myocardial infection, hypertension, and heart failure and identifies pharmacist interventions to minimize racial/ethnic disparities in cardiovascular disease state management.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Aleesha Jantzen, PharmD describes social determinants of health that impact management of cardiovascular disease states, recognizes racial/ethnic disparities in management of atrial fibrillation, myocardial infection, hypertension, and heart failure and identifies pharmacist interventions to minimize racial/ethnic disparities in cardiovascular disease state management.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 1983 121 full Nobody Likes Rejection: Therapeutic Drug Monitoring of Mycophenolate in Solid Organ Transplant Nobody Likes Rejection: Therapeutic Drug Monitoring of Mycophenolate in Solid Organ Transplant https://mayoclinicpharmacygrandrounds.podbean.com/e/nobody-likes-rejection-therapeutic-drug-monitoring-of-mycophenolate-in-solid-organ-transplant/ https://mayoclinicpharmacygrandrounds.podbean.com/e/nobody-likes-rejection-therapeutic-drug-monitoring-of-mycophenolate-in-solid-organ-transplant/#comments Wed, 08 Feb 2023 10:22:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/844bb6ce-1b76-3e4a-9424-64e5a287d782 Tanner A. Melton, PharmD (Twitter @TAMeltonRx) reviews factors associated with inter- and intra-patient mycophenolate pharmacokinetic variability, describes current strategies to perform mycophenolate therapeutic drug monitoring and determines an optimal monitoring plan for the treatment of a solid organ transplant recipient.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Tanner A. Melton, PharmD (Twitter @TAMeltonRx) reviews factors associated with inter- and intra-patient mycophenolate pharmacokinetic variability, describes current strategies to perform mycophenolate therapeutic drug monitoring and determines an optimal monitoring plan for the treatment of a solid organ transplant recipient.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2411 120 full Ascorbic Acid Episode IV: The Rise and Fall of Vitamin C Ascorbic Acid Episode IV: The Rise and Fall of Vitamin C https://mayoclinicpharmacygrandrounds.podbean.com/e/ascorbic-acid-episode-iv-the-rise-and-fall-of-vitamin-c/ https://mayoclinicpharmacygrandrounds.podbean.com/e/ascorbic-acid-episode-iv-the-rise-and-fall-of-vitamin-c/#comments Wed, 01 Feb 2023 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/d207c581-4808-3e12-aad1-e0de9d6417ab Mark P. Layden, PharmD, MBA (Twitter @Layden_Rx) describes the pathophysiology of sepsis and role of Vitamin C in the critically ill population, identifies the proposed benefits of Vitamin C use in the critically ill patient population and discusses updated literature on the current role of Vitamin C in sepsis.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mark P. Layden, PharmD, MBA (Twitter @Layden_Rx) describes the pathophysiology of sepsis and role of Vitamin C in the critically ill population, identifies the proposed benefits of Vitamin C use in the critically ill patient population and discusses updated literature on the current role of Vitamin C in sepsis.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2034 119 full Turning the Page on the Monoamine Story: Utilizing the NMDA Pathway for Major Depressive Disorder Turning the Page on the Monoamine Story: Utilizing the NMDA Pathway for Major Depressive Disorder https://mayoclinicpharmacygrandrounds.podbean.com/e/turning-the-page-on-the-monoamine-story-utilizing-the-nmda-pathway-for-major-depressive-disorder-1675097505/ https://mayoclinicpharmacygrandrounds.podbean.com/e/turning-the-page-on-the-monoamine-story-utilizing-the-nmda-pathway-for-major-depressive-disorder-1675097505/#comments Wed, 25 Jan 2023 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/6b01acc8-5f7d-3096-92a5-d0aea138708a Natalie T. Hagy, PharmD describes the monoamine and glutaminergic pathway for the treatment of major depressive disorder, recognizes response and remission rates of first line treatment for major depressive disorder and describes the clinical trials for dextromethorphan-bupropion and its impact on the landscape of major depressive disorder.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Natalie T. Hagy, PharmD describes the monoamine and glutaminergic pathway for the treatment of major depressive disorder, recognizes response and remission rates of first line treatment for major depressive disorder and describes the clinical trials for dextromethorphan-bupropion and its impact on the landscape of major depressive disorder.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2433 126 full Pump It Up: An Overview of Diabetic Insulin Pumps Pump It Up: An Overview of Diabetic Insulin Pumps https://mayoclinicpharmacygrandrounds.podbean.com/e/pump-it-up-an-overview-of-diabetic-insulin-pumps/ https://mayoclinicpharmacygrandrounds.podbean.com/e/pump-it-up-an-overview-of-diabetic-insulin-pumps/#comments Wed, 18 Jan 2023 14:11:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/a4a8e282-5909-327d-b2c5-366bef8f9ac6 Lauren R. Stonerock, PharmD (@LStonerockRx) reviews the history of insulin delivery technology and its impact on diabetes management, identifies patient-specific factors associated with successful insulin pump use and discusses current insulin pumps and highlight their specific features.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Lauren R. Stonerock, PharmD (@LStonerockRx) reviews the history of insulin delivery technology and its impact on diabetes management, identifies patient-specific factors associated with successful insulin pump use and discusses current insulin pumps and highlight their specific features.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2048 117 full “Rheum” for Improvement: Review of Rheumatoid Arthritis Treatment Guidelines “Rheum” for Improvement: Review of Rheumatoid Arthritis Treatment Guidelines https://mayoclinicpharmacygrandrounds.podbean.com/e/rheum-for-improvement-review-of-rheumatoid-arthritis-treatment-guidelines/ https://mayoclinicpharmacygrandrounds.podbean.com/e/rheum-for-improvement-review-of-rheumatoid-arthritis-treatment-guidelines/#comments Wed, 11 Jan 2023 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/a823d542-5c06-326c-9204-6da5f9b318ca Chelsea M. Morken, PharmD (@ChelseaMorken) explains the pathophysiology of rheumatoid arthritis (RA), describes the literature regarding cardiovascular risks with Janus-kinase inhibitors and recognizes appropriate initial therapy based on patient specific factors.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Chelsea M. Morken, PharmD (@ChelseaMorken) explains the pathophysiology of rheumatoid arthritis (RA), describes the literature regarding cardiovascular risks with Janus-kinase inhibitors and recognizes appropriate initial therapy based on patient specific factors.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2316 116 full Don’t You Know that You’re Toxic? Cardiotoxicity Prevention and Treatment in Oncology Don’t You Know that You’re Toxic? Cardiotoxicity Prevention and Treatment in Oncology https://mayoclinicpharmacygrandrounds.podbean.com/e/don-t-you-know-that-you-re-toxic-cardiotoxicity-prevention-and-treatment-in-oncology/ https://mayoclinicpharmacygrandrounds.podbean.com/e/don-t-you-know-that-you-re-toxic-cardiotoxicity-prevention-and-treatment-in-oncology/#comments Wed, 04 Jan 2023 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/0930b594-cc56-35ee-b474-b4185526a96c Uzoamaka (Uzo) C. Abajue, PharmD (@Uzo_Chi) discusses the manifestations, diagnosis, and classification of chemotherapy induced cardiotoxicity, identifies causative oncologic agents responsible for cardiotoxicities and outlines strategies for cardiotoxicity management due to oncologic agents.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Uzoamaka (Uzo) C. Abajue, PharmD (@Uzo_Chi) discusses the manifestations, diagnosis, and classification of chemotherapy induced cardiotoxicity, identifies causative oncologic agents responsible for cardiotoxicities and outlines strategies for cardiotoxicity management due to oncologic agents.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 1707 115 full Mab Scientists: Therapeutic Drug Monitoring with Eculizumab Mab Scientists: Therapeutic Drug Monitoring with Eculizumab https://mayoclinicpharmacygrandrounds.podbean.com/e/mab-scientists-therapeutic-drug-monitoring-with-eculizumab/ https://mayoclinicpharmacygrandrounds.podbean.com/e/mab-scientists-therapeutic-drug-monitoring-with-eculizumab/#comments Wed, 28 Dec 2022 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/ef117df6-923c-3694-99da-eca54db6261d Megan A. Galle, PharmD (@meganciclovir) reviews eculizumab’s mechanism of action and its role in treating antibody mediated rejection following solid organ transplantation, discusses laboratory testing methods available for eculizumab therapeutic drug monitoring and describes the role of therapeutic drug monitoring in eculizumab treatment optimization.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Megan A. Galle, PharmD (@meganciclovir) reviews eculizumab’s mechanism of action and its role in treating antibody mediated rejection following solid organ transplantation, discusses laboratory testing methods available for eculizumab therapeutic drug monitoring and describes the role of therapeutic drug monitoring in eculizumab treatment optimization.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 1491 114 full Pharmacy’s Fantastic when the Marrows Aplastic: Pharmacologic Management of Aplastic Anemia Pharmacy’s Fantastic when the Marrows Aplastic: Pharmacologic Management of Aplastic Anemia https://mayoclinicpharmacygrandrounds.podbean.com/e/pharmacy-s-fantastic-when-the-marrows-aplastic-pharmacologic-management-of-aplastic-anemia/ https://mayoclinicpharmacygrandrounds.podbean.com/e/pharmacy-s-fantastic-when-the-marrows-aplastic-pharmacologic-management-of-aplastic-anemia/#comments Wed, 21 Dec 2022 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/dff8559a-53c1-3620-bb10-46bababad044 Devon S. Stonerock, PharmD (@DevonStoneRx) describes the underlying pathophysiology driving the development and progression of aplastic anemia, outlines treatment options based on patient specific factors and recognizes key toxicities, drug interactions, and administration considerations for patients receiving immunosuppressive therapy.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Devon S. Stonerock, PharmD (@DevonStoneRx) describes the underlying pathophysiology driving the development and progression of aplastic anemia, outlines treatment options based on patient specific factors and recognizes key toxicities, drug interactions, and administration considerations for patients receiving immunosuppressive therapy.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2255 113 full It’s in the Genes: Identification and Treatment of ESBL-E It’s in the Genes: Identification and Treatment of ESBL-E https://mayoclinicpharmacygrandrounds.podbean.com/e/it-s-in-the-genes-identification-and-treatment-of-esbl-e/ https://mayoclinicpharmacygrandrounds.podbean.com/e/it-s-in-the-genes-identification-and-treatment-of-esbl-e/#comments Wed, 14 Dec 2022 11:31:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/7d2a10fe-8233-3907-bf2d-f16180a12d8f Sarah A. Chase, PharmD identifies the most common ESBL-producing bacteria and common ESBL resistance genes, recognizes the use and limitations in using phenotypic and genotypic data to identify potential ESBL-E organisms and discusses clinical trial data and IDSA guidance to assist in the selection of appropriate antimicrobials for the treatment of ESBL-E infections .

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Sarah A. Chase, PharmD identifies the most common ESBL-producing bacteria and common ESBL resistance genes, recognizes the use and limitations in using phenotypic and genotypic data to identify potential ESBL-E organisms and discusses clinical trial data and IDSA guidance to assist in the selection of appropriate antimicrobials for the treatment of ESBL-E infections .

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 1869 112 full Early Multimodal Vasopressors in Septic Shock: When is it Time for Full-Court Press(ors)? Early Multimodal Vasopressors in Septic Shock: When is it Time for Full-Court Press(ors)? https://mayoclinicpharmacygrandrounds.podbean.com/e/early-multimodal-vasopressors-in-septic-shock-when-is-it-time-for-full-court-pressors/ https://mayoclinicpharmacygrandrounds.podbean.com/e/early-multimodal-vasopressors-in-septic-shock-when-is-it-time-for-full-court-pressors/#comments Wed, 07 Dec 2022 11:21:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/066f1748-43f4-31ac-85e7-09ef6d99f2e3 Kyle A. Hess, PharmD (@KyleHessPHarmD) describes the rationale for early use of vasopressors with multiple mechanisms of action in patients with septic shock, reviews the literature examining the early initiation of vasopressin in patients with septic shock and identifies patient characteristics associated with positive response to angiotensin II.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Kyle A. Hess, PharmD (@KyleHessPHarmD) describes the rationale for early use of vasopressors with multiple mechanisms of action in patients with septic shock, reviews the literature examining the early initiation of vasopressin in patients with septic shock and identifies patient characteristics associated with positive response to angiotensin II.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 1828 111 full The R(igh)T Way or the Highway: Pharmacologic Management of Radiation Therapy (RT) Toxicities The R(igh)T Way or the Highway: Pharmacologic Management of Radiation Therapy (RT) Toxicities https://mayoclinicpharmacygrandrounds.podbean.com/e/the-right-way-or-the-highway-pharmacologic-management-of-radiation-therapy-rt-toxicities/ https://mayoclinicpharmacygrandrounds.podbean.com/e/the-right-way-or-the-highway-pharmacologic-management-of-radiation-therapy-rt-toxicities/#comments Wed, 30 Nov 2022 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/cf651e4d-c29a-3416-89f7-d243de1dfd40 Divya A. Khandekar, PharmD, MS (@pharmdiv) discusses the basic principles of radiation therapy in the treatment of cancer, describes the etiology and pathophysiology of toxicities caused by radiation therapy and identifies which pharmacological treatments for radiation toxicity management are evidence-based.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Divya A. Khandekar, PharmD, MS (@pharmdiv) discusses the basic principles of radiation therapy in the treatment of cancer, describes the etiology and pathophysiology of toxicities caused by radiation therapy and identifies which pharmacological treatments for radiation toxicity management are evidence-based.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2341 110 full The Unit that Never Sleeps: Pharmacologic Sleep Agents for Critically Ill Patients The Unit that Never Sleeps: Pharmacologic Sleep Agents for Critically Ill Patients https://mayoclinicpharmacygrandrounds.podbean.com/e/the-unit-that-never-sleeps-pharmacologic-sleep-agents-for-critically-ill-patients/ https://mayoclinicpharmacygrandrounds.podbean.com/e/the-unit-that-never-sleeps-pharmacologic-sleep-agents-for-critically-ill-patients/#comments Wed, 23 Nov 2022 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/d075cde2-570e-339d-89e4-a41e3cadce7d Nikitha Yagnala, PharmD (@nikithayagnala) recognizes the physiologic consequences of sleep disturbances in critically ill patients, discusses the mechanisms of sleep promotion for pharmacologic sleep agents and outlines appropriate utilization of pharmacologic sleep agents in critically ill patients.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Nikitha Yagnala, PharmD (@nikithayagnala) recognizes the physiologic consequences of sleep disturbances in critically ill patients, discusses the mechanisms of sleep promotion for pharmacologic sleep agents and outlines appropriate utilization of pharmacologic sleep agents in critically ill patients.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2422 109 full Fluid Stewardship in the ICU: The Rush to De-resuscitate Fluid Stewardship in the ICU: The Rush to De-resuscitate https://mayoclinicpharmacygrandrounds.podbean.com/e/fluid-stewardship-in-the-icu-the-rush-to-de-resuscitate/ https://mayoclinicpharmacygrandrounds.podbean.com/e/fluid-stewardship-in-the-icu-the-rush-to-de-resuscitate/#comments Wed, 16 Nov 2022 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/eb9256cb-5f72-38bb-9c75-65b940040e4e Andrew J. Jatis, PharmD (Twittter:@jatis_rx) Identifies adverse consequences of fluid overload in critically ill patients, summarizes literature assessing the efficacy and safety of fluid stewardship strategies and generates patient-specific plans for fluid management based on available evidence.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Andrew J. Jatis, PharmD (Twittter:@jatis_rx) Identifies adverse consequences of fluid overload in critically ill patients, summarizes literature assessing the efficacy and safety of fluid stewardship strategies and generates patient-specific plans for fluid management based on available evidence.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2339 108 full A CYmPle Matter – CYP2C19 Polymorphisms and P2Y12 Inhibitor Selection in Ischemic Stroke A CYmPle Matter – CYP2C19 Polymorphisms and P2Y12 Inhibitor Selection in Ischemic Stroke https://mayoclinicpharmacygrandrounds.podbean.com/e/a-cymple-matter-%e2%80%93-cyp2c19-polymorphisms-and-p2y12-inhibitor-selection-in-ischemic-stroke/ https://mayoclinicpharmacygrandrounds.podbean.com/e/a-cymple-matter-%e2%80%93-cyp2c19-polymorphisms-and-p2y12-inhibitor-selection-in-ischemic-stroke/#comments Wed, 09 Nov 2022 06:00:00 -0600 mayoclinicpharmacygrandrounds.podbean.com/76dc54aa-25f8-3244-bee9-1d6ddea6a59b Jo Ann Leal, PharmD (Twitter: @jojopharmd) describes the implications of various CYP2C19 phenotypes on clopidogrel metabolism and activity, analyzes the available literature evaluating outcomes of clopidogrel versus ticagrelor in ischemic stroke patients based on CYP2C19 metabolizer status and selects a preferred antiplatelet agent and dose for secondary prevention of ischemic stroke given patient specific pharmacogenomic information.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Jo Ann Leal, PharmD (Twitter: @jojopharmd) describes the implications of various CYP2C19 phenotypes on clopidogrel metabolism and activity, analyzes the available literature evaluating outcomes of clopidogrel versus ticagrelor in ischemic stroke patients based on CYP2C19 metabolizer status and selects a preferred antiplatelet agent and dose for secondary prevention of ischemic stroke given patient specific pharmacogenomic information.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2447 107 full Pediatric Updates on Transplant Associated-Thrombotic Microangiopathy (TA-TMA) Pediatric Updates on Transplant Associated-Thrombotic Microangiopathy (TA-TMA) https://mayoclinicpharmacygrandrounds.podbean.com/e/pediatric-updates-on-transplant-associated-thrombotic-microangiopathy-ta-tma/ https://mayoclinicpharmacygrandrounds.podbean.com/e/pediatric-updates-on-transplant-associated-thrombotic-microangiopathy-ta-tma/#comments Wed, 19 Oct 2022 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/8e12fc84-9bc6-35c4-834f-f8fc2f55733b KaShena L. Kennedy, PharmD (Twitter: @KaShenaKennedy) reviews and identifies the pathophysiology, clinical manifestations, and diagnostic criteria for TA-TMA in pediatric patients, differentiates risk factors associated with TA-TMA and discusses prophylactic treatment in pediatric patients and explores treatment and emerging therapy options of TA-TMA in pediatric patients.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> KaShena L. Kennedy, PharmD (Twitter: @KaShenaKennedy) reviews and identifies the pathophysiology, clinical manifestations, and diagnostic criteria for TA-TMA in pediatric patients, differentiates risk factors associated with TA-TMA and discusses prophylactic treatment in pediatric patients and explores treatment and emerging therapy options of TA-TMA in pediatric patients.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2318 106 full Time for a Heart-to-Heart: ADAPTing Antithrombotic Therapy Post-TAVR Time for a Heart-to-Heart: ADAPTing Antithrombotic Therapy Post-TAVR https://mayoclinicpharmacygrandrounds.podbean.com/e/time-for-a-heart-to-heart-adapting-antithrombotic-therapy-post-tavr/ https://mayoclinicpharmacygrandrounds.podbean.com/e/time-for-a-heart-to-heart-adapting-antithrombotic-therapy-post-tavr/#comments Wed, 12 Oct 2022 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/dc12307f-6bdc-334c-a57d-2b3e6675a014 Aeryana Beaudrie-Nunn, PharmD (Twitter: @ABeaudrieRx) identifies the rationale for antithrombotic therapy following TAVR, reviews the utility of direct oral anticoagulants after TAVR considering recent clinical trial data and defines the patient context where direct oral anticoagulant use following TAVR is most appropriate.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Aeryana Beaudrie-Nunn, PharmD (Twitter: @ABeaudrieRx) identifies the rationale for antithrombotic therapy following TAVR, reviews the utility of direct oral anticoagulants after TAVR considering recent clinical trial data and defines the patient context where direct oral anticoagulant use following TAVR is most appropriate.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 1981 105 full Dual Antiplatelet Therapy Following PCI: Choosing a SMART-DATE to STOP-DAPT Dual Antiplatelet Therapy Following PCI: Choosing a SMART-DATE to STOP-DAPT https://mayoclinicpharmacygrandrounds.podbean.com/e/dual-antiplatelet-therapy-following-pci-choosing-a-smart-date-to-stop-dapt/ https://mayoclinicpharmacygrandrounds.podbean.com/e/dual-antiplatelet-therapy-following-pci-choosing-a-smart-date-to-stop-dapt/#comments Wed, 05 Oct 2022 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/662195e7-5510-3ebc-9174-7e8ba6a2169d Kyle A. Hess, PharmD (Twitter: @KyleHessPharmD ) describes current guideline recommendations for duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention, compares and contrasts strategies for antiplatelet regimens for reduced duration DAPT and selects an appropriate duration of therapy when utilizing shortened DAPT.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Kyle A. Hess, PharmD (Twitter: @KyleHessPharmD ) describes current guideline recommendations for duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention, compares and contrasts strategies for antiplatelet regimens for reduced duration DAPT and selects an appropriate duration of therapy when utilizing shortened DAPT.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 1906 104 full Level Up: Updates on Direct Oral Anticoagulant Plasma Levels Level Up: Updates on Direct Oral Anticoagulant Plasma Levels https://mayoclinicpharmacygrandrounds.podbean.com/e/level-up-updates-on-direct-oral-anticoagulant-plasma-levels/ https://mayoclinicpharmacygrandrounds.podbean.com/e/level-up-updates-on-direct-oral-anticoagulant-plasma-levels/#comments Wed, 28 Sep 2022 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/3e0b67da-fdef-3070-83c2-8eb14cbd9fce Nikitha Yagnala, PharmD (Twitter: @NikithaYagnala) describes laboratory tests used to estimate DOAC plasma levels, reviews current literature exploring the association between DOAC plasma levels and clinical outcomes and outlines appropriate utilization and interpretation of DOAC plasma levels in clinical practice.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Nikitha Yagnala, PharmD (Twitter: @NikithaYagnala) describes laboratory tests used to estimate DOAC plasma levels, reviews current literature exploring the association between DOAC plasma levels and clinical outcomes and outlines appropriate utilization and interpretation of DOAC plasma levels in clinical practice.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2279 103 full Is Shorter Better? Early Discontinuation of Empiric Antibiotics in Febrile Neutropenia Is Shorter Better? Early Discontinuation of Empiric Antibiotics in Febrile Neutropenia https://mayoclinicpharmacygrandrounds.podbean.com/e/is-shorter-better-early-discontinuation-of-empiric-antibiotics-in-febrile-neutropenia/ https://mayoclinicpharmacygrandrounds.podbean.com/e/is-shorter-better-early-discontinuation-of-empiric-antibiotics-in-febrile-neutropenia/#comments Wed, 21 Sep 2022 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/03506243-1789-357a-99eb-4ebefea47a28 Divya A. Khandekar, PharmD, MS (Twitter: @pharmdiv) describes the etiology of febrile neutropenia in patients with hematological malignancies, summarizes guideline-based recommendations for antibiotic discontinuation in patients with febrile neutropenia and discusses primary literature supporting early antibiotic discontinuation in patients with febrile neutropenia.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Divya A. Khandekar, PharmD, MS (Twitter: @pharmdiv) describes the etiology of febrile neutropenia in patients with hematological malignancies, summarizes guideline-based recommendations for antibiotic discontinuation in patients with febrile neutropenia and discusses primary literature supporting early antibiotic discontinuation in patients with febrile neutropenia.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2353 102 full Long Acting Lipoglycopeptides: Antibiotic Friend or Foe? Long Acting Lipoglycopeptides: Antibiotic Friend or Foe? https://mayoclinicpharmacygrandrounds.podbean.com/e/long-acting-lipoglycopeptides-antibiotic-friend-or-foe/ https://mayoclinicpharmacygrandrounds.podbean.com/e/long-acting-lipoglycopeptides-antibiotic-friend-or-foe/#comments Wed, 14 Sep 2022 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/9fa887c8-ba50-3554-809b-430531c58cef Andrew J. Jatis, PharmD (Twitter: @jatis_rx) reviews the pharmacology and drug characteristics of dalbavancin and oritavancin, describes current literature assessing the safety and efficacy of FDA approved and off-label indications for lipoglycopeptide use in clinical practice and discusses pharmacoeconomic implications of lipoglycopeptide use in clinical practice.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Andrew J. Jatis, PharmD (Twitter: @jatis_rx) reviews the pharmacology and drug characteristics of dalbavancin and oritavancin, describes current literature assessing the safety and efficacy of FDA approved and off-label indications for lipoglycopeptide use in clinical practice and discusses pharmacoeconomic implications of lipoglycopeptide use in clinical practice.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2601 101 full Strategies to Reduce Relapse after Hematopoietic Cell Transplantation Strategies to Reduce Relapse after Hematopoietic Cell Transplantation https://mayoclinicpharmacygrandrounds.podbean.com/e/strategies-to-reduce-relapse-after-hematopoietic-cell-transplantation/ https://mayoclinicpharmacygrandrounds.podbean.com/e/strategies-to-reduce-relapse-after-hematopoietic-cell-transplantation/#comments Wed, 07 Sep 2022 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/5a4df86d-fe8b-350a-95cf-7dbd13d9451c Kaylee A. Clark, PharmD describes the basic principles of maintenance therapies after allogeneic HSCT, discusses evidence and guideline recommendations for maintenance therapies after allogeneic HSCT for acute lymphoblastic leukemia and reviews evidence and guideline recommendations for maintenance therapies after allogeneic HSCT for acute myeloid leukemia.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Kaylee A. Clark, PharmD describes the basic principles of maintenance therapies after allogeneic HSCT, discusses evidence and guideline recommendations for maintenance therapies after allogeneic HSCT for acute lymphoblastic leukemia and reviews evidence and guideline recommendations for maintenance therapies after allogeneic HSCT for acute myeloid leukemia.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2164 100 full Process Management Techniques to Improve Patient Safety Process Management Techniques to Improve Patient Safety https://mayoclinicpharmacygrandrounds.podbean.com/e/process-management-techniques-to-improve-patient-safety/ https://mayoclinicpharmacygrandrounds.podbean.com/e/process-management-techniques-to-improve-patient-safety/#comments Wed, 31 Aug 2022 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/29a5ef14-fb97-3457-8a9a-3da9ed7fac72 Kyle J. Eickman, PharmD, describe the goals of six sigma methodology and review examples of its application within pharmacy dispensing, reviews DMAIC methodology and describes how lean and six sigma can be used to achieve the same goals of patient safety. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Kyle J. Eickman, PharmD, describe the goals of six sigma methodology and review examples of its application within pharmacy dispensing, reviews DMAIC methodology and describes how lean and six sigma can be used to achieve the same goals of patient safety. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2247 99 full Let’s Take It One CYP At a Time: Unraveling the Role of CYP2B6 in Methadone Metabolism Let’s Take It One CYP At a Time: Unraveling the Role of CYP2B6 in Methadone Metabolism https://mayoclinicpharmacygrandrounds.podbean.com/e/let-s-take-it-one-cyp-at-a-time-unraveling-the-role-of-cyp2b6-in-methadone-metabolism/ https://mayoclinicpharmacygrandrounds.podbean.com/e/let-s-take-it-one-cyp-at-a-time-unraveling-the-role-of-cyp2b6-in-methadone-metabolism/#comments Wed, 24 Aug 2022 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/a912c441-5a75-3dd6-87c1-83dbfe57848a Dimple R. Dhakal, PharmD describes the pharmacodynamics and pharmacokinetics of methadone, identifies and discusses clinical practice guidelines for the safe use of methadone and evaluates evidence for CYP2B6-guided methadone use.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Dimple R. Dhakal, PharmD describes the pharmacodynamics and pharmacokinetics of methadone, identifies and discusses clinical practice guidelines for the safe use of methadone and evaluates evidence for CYP2B6-guided methadone use.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2357 98 full Opioid Stewardship: A Focus on Opioids at Transitions of Care Opioid Stewardship: A Focus on Opioids at Transitions of Care https://mayoclinicpharmacygrandrounds.podbean.com/e/opioid-stewardship-a-focus-on-opioids-at-transitions-of-care/ https://mayoclinicpharmacygrandrounds.podbean.com/e/opioid-stewardship-a-focus-on-opioids-at-transitions-of-care/#comments Wed, 17 Aug 2022 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/25500b57-c8d3-31cf-9ace-8366444116ed Julie L. Cunningham, PharmD, BCPP; M. Zeeshan Rizwan, PharmD, BCPS, BCCCP; Christi A. Jen, PharmD, BCPS, FASHP, FAzPA; and Kristina L. Wescott, PharmD, BCPS identify appropriate non-stigmatizing language related to opioids and addiction in the context of patient care discussions, discuss risks for opioid harms related to individual risks at points of transitions of patient care, review interventions for high-risk opioid patients across transitions of care and identify resources in multiple areas of practice to support patient care for opioid use.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Julie L. Cunningham, PharmD, BCPP; M. Zeeshan Rizwan, PharmD, BCPS, BCCCP; Christi A. Jen, PharmD, BCPS, FASHP, FAzPA; and Kristina L. Wescott, PharmD, BCPS identify appropriate non-stigmatizing language related to opioids and addiction in the context of patient care discussions, discuss risks for opioid harms related to individual risks at points of transitions of patient care, review interventions for high-risk opioid patients across transitions of care and identify resources in multiple areas of practice to support patient care for opioid use.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2346 97 full When the Beat Drops: Pharmacotherapy in Cardiac Arrest When the Beat Drops: Pharmacotherapy in Cardiac Arrest https://mayoclinicpharmacygrandrounds.podbean.com/e/when-the-beat-drops-pharmacotherapy-in-cardiac-arrest/ https://mayoclinicpharmacygrandrounds.podbean.com/e/when-the-beat-drops-pharmacotherapy-in-cardiac-arrest/#comments Wed, 10 Aug 2022 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/b6ddf522-e472-3743-bd68-c1f0c1bd68ec Hannah M. Brokmeier, PharmD, describes the pathophysiology behind the pharmacologic targets in ACLS, discusses the role of vasopressin, steroids, and epinephrine in cardiac arrest management, and explains the mechanism and evidence behind administering adjunct agents during ACLS.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Hannah M. Brokmeier, PharmD, describes the pathophysiology behind the pharmacologic targets in ACLS, discusses the role of vasopressin, steroids, and epinephrine in cardiac arrest management, and explains the mechanism and evidence behind administering adjunct agents during ACLS.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2198 96 full To Augmentation and Beyond: Strategies for Treatment-Resistant Depression To Augmentation and Beyond: Strategies for Treatment-Resistant Depression https://mayoclinicpharmacygrandrounds.podbean.com/e/to-augmentation-and-beyond-strategies-for-treatment-resistant-depression/ https://mayoclinicpharmacygrandrounds.podbean.com/e/to-augmentation-and-beyond-strategies-for-treatment-resistant-depression/#comments Wed, 27 Jul 2022 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/799d221f-5dfe-3be5-b41a-15b078178536 Lauren M. Dolly, PharmD, recalls the etiology and pathophysiology of TRD, discusses the role of pharmacogenomics in L-methylfolate for TRD, selects a preferred agent for a patient with TRD with evidence to support its use.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Lauren M. Dolly, PharmD, recalls the etiology and pathophysiology of TRD, discusses the role of pharmacogenomics in L-methylfolate for TRD, selects a preferred agent for a patient with TRD with evidence to support its use.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2539 95 full Oops! AI Did It Again! Oops! AI Did It Again! https://mayoclinicpharmacygrandrounds.podbean.com/e/oops-ai-did-it-again/ https://mayoclinicpharmacygrandrounds.podbean.com/e/oops-ai-did-it-again/#comments Wed, 20 Jul 2022 06:00:00 -0500 mayoclinicpharmacygrandrounds.podbean.com/8c5b8670-0151-38db-9d0b-ddfcd0c50dc7 Pooja Ojha, PharmD, describes what bias in artificial intelligence entails, discusses implications of bias in artificial intelligence, evaluates mitigation strategies for bias in artificial intelligence.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Pooja Ojha, PharmD, describes what bias in artificial intelligence entails, discusses implications of bias in artificial intelligence, evaluates mitigation strategies for bias in artificial intelligence.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

]]> Mayo Clinic false No 2614 94 full